HUP0000088A2 - N-Szubsztituált azaheterociklusos vegyületek, eljárás előállításukra, valamint ezeket a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents

N-Szubsztituált azaheterociklusos vegyületek, eljárás előállításukra, valamint ezeket a vegyületeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0000088A2
HUP0000088A2 HU0000088A HUP0000088A HUP0000088A2 HU P0000088 A2 HUP0000088 A2 HU P0000088A2 HU 0000088 A HU0000088 A HU 0000088A HU P0000088 A HUP0000088 A HU P0000088A HU P0000088 A2 HUP0000088 A2 HU P0000088A2
Authority
HU
Hungary
Prior art keywords
compounds
producing
pharmaceutical compositions
compositions containing
substituted azaheterocyclic
Prior art date
Application number
HU0000088A
Other languages
English (en)
Inventor
Knud Erik Andersen
Rolf Hohlweg
Tine Krogh Jorgensen
Tomas Kalisz
Peter Ulvebjerg Madsen
Uffe Bang Olsen
Zdenek Polivka
Alexandra Silhankova
Karel Sindelar
Svend Treppendahl
Vladimir Valenta
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of HUP0000088A2 publication Critical patent/HUP0000088A2/hu
Publication of HUP0000088A3 publication Critical patent/HUP0000088A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány tárgyát képezik az (I) általánős képletű új, N-szűbsztitűált azaheterőciklűsős vegyületek, gyógyászati szempőntbólalkalmazható sóik, az említett vegyületek előállítására szőlgálóeljárásők, az említett vegyületeket tartalmazó gyógyszerkészítményekés felhasználásűk az őlyan fájdalmas, hiperalgéziás és/vagygyűlladásős állapőtők klinikai kezelésére, ahől a C-idegrőstőkkórélettani szerepet játszanak a neűrőgén fájdalőm vagy gyűlladáskiváltásában, tővábbá azőn indikációk kezelésére, melyeket azinzűlinnal antagőnizáló peptidek kiválasztása és vérkeringésbekerülése vált ki, vagy azzal hőzhatók kapcsőlatba. ŕ
HU0000088A 1996-10-04 1997-10-02 N-substituted azaheterocyclic compounds, process for producing them and pharmaceutical compositions containing them HUP0000088A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK108996 1996-10-04
PCT/DK1997/000421 WO1998015546A1 (en) 1996-10-04 1997-10-02 N-substituted azaheterocyclic compounds

Publications (2)

Publication Number Publication Date
HUP0000088A2 true HUP0000088A2 (hu) 2000-06-28
HUP0000088A3 HUP0000088A3 (en) 2000-09-28

Family

ID=8100875

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000088A HUP0000088A3 (en) 1996-10-04 1997-10-02 N-substituted azaheterocyclic compounds, process for producing them and pharmaceutical compositions containing them

Country Status (14)

Country Link
US (1) US6569849B1 (hu)
EP (1) EP0934306A1 (hu)
JP (1) JP2001501629A (hu)
KR (1) KR20000048909A (hu)
CN (1) CN1234797A (hu)
AU (1) AU741839B2 (hu)
BR (1) BR9712202A (hu)
CA (1) CA2267500A1 (hu)
CZ (1) CZ114199A3 (hu)
HU (1) HUP0000088A3 (hu)
IL (1) IL129122A0 (hu)
NO (1) NO991563L (hu)
PL (1) PL332593A1 (hu)
WO (1) WO1998015546A1 (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2319077A1 (en) 1998-01-21 1999-07-29 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6613905B1 (en) 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2318088A1 (en) * 1998-01-21 1999-07-29 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
US7271176B2 (en) 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
WO2004112705A2 (en) * 2003-06-16 2004-12-29 Hypnion, Inc. Methods for treating sleep disorders
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
EP2565183A1 (en) 2006-06-28 2013-03-06 Amgen Inc. Glycine transporter-1 inhibitors
US8034940B2 (en) 2006-08-09 2011-10-11 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
SE531698C2 (sv) 2007-07-12 2009-07-07 Respiratorius Ab Nya bronkdilaterande a,b-omättade amider
WO2009015359A2 (en) 2007-07-26 2009-01-29 Cellay, Llc Highly visible chromosome-specific probes and related methods
CN107595841A (zh) 2009-01-09 2018-01-19 得克萨斯州大学系统董事会 前神经原性化合物
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
BR112012030813A2 (pt) 2010-06-03 2017-06-20 Cellay Inc "métodos e kits para detecção in situ de sequências de nucleotídeo"
WO2012006419A2 (en) 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2013026455A1 (en) * 2011-08-24 2013-02-28 Aarhus Universitet Permanently positively charged antidepressants
CN104145027A (zh) 2011-12-12 2014-11-12 塞雷公司 用于室温原位检测生物样品中的目标核酸的方法和试剂盒
EP2887803A4 (en) * 2012-08-24 2016-08-03 Univ Texas PRO-NEUROGENIC COMPOUNDS
US8877441B2 (en) 2012-10-31 2014-11-04 Cellay, Inc. Methods and kits for performing in situ hybridization
WO2015069920A1 (en) 2013-11-07 2015-05-14 Cellay, Inc. Methods and kits for detecting a prostate carcinoma and predicting disease outcomes for prostate cancers
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
CN111171006B (zh) * 2020-01-29 2023-05-12 成都睿智化学研究有限公司 一种3-取代亚氨基二苄氨基类化合物的工艺方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3123610A (en) * 1964-03-03 Alkanoylpiperidinoalkyl
US3058979A (en) * 1957-05-13 1962-10-16 Smith Kline French Lab New perfluoroalkylphenothiazine derivatives
FR1212031A (fr) * 1957-10-21 1960-03-21 Rhone Poulenc Sa Dérivés de la phénothiazine substitués à l'azote par une chaîne basique comportant un hétérocycle et leur préparation
BE566958A (hu) * 1958-04-19
CH374682A (de) * 1959-08-28 1964-01-31 Geigy Ag J R Verfahren zur Herstellung von neuen N-heterocyclischen Verbindungen
FR1578748A (hu) * 1967-12-28 1969-08-22
DE1920170A1 (de) * 1968-04-20 1970-01-29 Egyt Gyogyszervegyeszeti Gyar Verfahren zur Herstellung von N-Heterocyclischen Verbindungen
NO127151B (hu) * 1969-03-28 1973-05-14 Ciba Geigy Ag
FR2005201B1 (hu) * 1969-05-20 1973-03-16 Auguil Ste Civile
GB1347935A (en) * 1971-04-10 1974-02-27 Yoshitomi Pharmaceutical Piperazine derivatives methods for their production and phar maceutical compositions containing them
US3828034A (en) * 1972-05-25 1974-08-06 Syntex Inc Tricyclic pharmacological agents,intermediates and methods of making
FR2186249A1 (en) * 1972-05-31 1974-01-11 Synthelabo Phenyl piperazinoalkyl (dihydro)dibenzazepines - antidepressants having low toxicity
US3965181A (en) * 1973-07-06 1976-06-22 Syntex (U.S.A.) Inc. Tricyclic pharmacological agents, intermediates and methods of making
GB1480593A (en) * 1973-11-30 1977-07-20 Kefalas As Xanthene and thioxanthene derivatives having pharmaceutical activity
DE3444837A1 (de) * 1984-12-08 1986-06-12 Basf Ag, 6700 Ludwigshafen 10,11-dihydro-5h-dibenzo(a,d)cycloheptadien- derivate, ihre herstellung und verwendung
MY113463A (en) 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
US5716949A (en) * 1995-04-07 1998-02-10 Novo Nordisk A/S Heterocyclic compounds
DK0934312T3 (da) * 1996-10-04 2003-07-21 Novo Nordisk As 1,4-disubstituerede piperaziner
US6040318A (en) * 1997-06-25 2000-03-21 Novo Nordisk A/S Tricycle substituted with azaheterocyclic carboxylic acids

Also Published As

Publication number Publication date
US6569849B1 (en) 2003-05-27
NO991563L (no) 1999-06-03
EP0934306A1 (en) 1999-08-11
HUP0000088A3 (en) 2000-09-28
CN1234797A (zh) 1999-11-10
CA2267500A1 (en) 1998-04-16
NO991563D0 (no) 1999-03-30
PL332593A1 (en) 1999-09-27
WO1998015546A1 (en) 1998-04-16
BR9712202A (pt) 1999-08-31
AU4377197A (en) 1998-05-05
CZ114199A3 (cs) 1999-09-15
AU741839B2 (en) 2001-12-13
KR20000048909A (ko) 2000-07-25
IL129122A0 (en) 2000-02-17
JP2001501629A (ja) 2001-02-06

Similar Documents

Publication Publication Date Title
HUP0000088A2 (hu) N-Szubsztituált azaheterociklusos vegyületek, eljárás előállításukra, valamint ezeket a vegyületeket tartalmazó gyógyszerkészítmények
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
RU94045155A (ru) Способы ингибирования болезни альцгеймера
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
DE3779500D1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
ES2054995T3 (es) Nuevos derivados del acido benzoico y acido fenilacetico, su obtencion y empleo como medicamentos.
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
RU93004484A (ru) Производные пиразола, способ их получения и содержащие их фармацевтические композиции
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
AR028988A1 (es) Derivados amida, proceso para su preparacion, composicion farmaceutica que los comprende, y su uso en la fabricacion de un medicamento util en el tratamiento de enfermedades o afecciones clinicas mediadas por citoquinas
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
SE0104340D0 (sv) New compounds
NO306295B1 (no) Heterosykliske forbindelser, farmasöytiske preparater som omfatter slike forbindelser, samt anvendelse av forbindelsene til fremstilling av medikamenter
LU88317I2 (fr) Chlorhydrate d'esmolol (Brevibloc)
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
ES2157005T3 (es) Uso del acido boswellico y sus derivados para la inhibicion de la actividad normal y elevada de la elastasa de leucocitos o de la plasmina.
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
ATE198550T1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
DE58901002D1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
PT1147105E (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente activo e sua utilizacao no tratamento de doencas vasculares
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
DK0538690T3 (da) Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler